Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-LockTM platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.
Location: United States, California, San Diego
Employees: 11-50
Total raised: $161M
Investors 2
| Date | Name | Website |
| - | Avalon Bio... | avalonbiov... |
| - | Frazier Li... | frazierls.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.05.2024 | Series A | $100M | - |
| 12.10.2022 | Seed | $61M | - |
Mentions in press and media 6
| Date | Title | Description |
| 03.05.2024 | Enlaza Therapeutics Secures $100M in Series A Funding | Enlaza Therapeutics, a La Jolla-based company specializing in protein drugs, has successfully raised $100M in a Series A financing round. The funding was spearheaded by the Life Sciences Group of J.P. Morgan Private Capital, with support fr... |
| 02.05.2024 | Enlaza Therapeutics Finds $100M | La Jolla-based Enlaza Therapeutics, which is working on protein drugs, says it has raised $100M in a Series A financing round. The funding was led by Life Sciences Group of J.P. Morgan Private Capital, and also included existing investors F... |
| 30.04.2024 | Enlaza Therapeutics Raises $100M in Series A Financing | Enlaza Therapeutics, a La Jolla, CA-based covalent biologic platform company, raised $100M in Series A funding. The round was led by Life Sciences group of J.P. Morgan Asset Management’s Private Capital division, with participation from exi... |
| 19.12.2022 | Enlaza Therapeutics Raises $61M in Seed Financing | Enlaza Therapeutics, a La Jolla, CA-based covalent biologic company, raised $61M in Seed financing. The round was led by Avalon Ventures, with participation from Lightspeed Venture Partners, Frazier Life Sciences, and Samsara BioCapital. Th... |
| - | Enlaza Therapeutics: Covalent Biologic Platform Company Secures $100 Million | Covalent biologic platform company Enlaza Therapeutics announced a $100 million Series A funding round. This round of funding will be used to develop Enlaza’s proprietary covalent protein technologies further and support the advancement of ... |
| - | Enlaza Therapeutics | “Enlaza Therapeutics is pioneering the field of covalent biologics, developing a novel classes of protein therapeutics based on its proprietary War-Lock™ platform.” |